Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
- Details
- Category: Genzyme
Genzyme Corporation (NASDAQ: GENZ) recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL Awards).
Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab)
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(R) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases.
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy
- Details
- Category: Bayer
Bayer HealthCare and Onyx Pharmaceuticals, Inc. announced that the companies have begun enrolling patients in a Phase III randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) announces 2010 results, which meet all financial expectations. Full year revenue was DKK 14,765 million and increased 7% compared to 2009, driven by a positive development in all regions.
Sanofi Pasteur and International Vaccine Institute Partner against Dengue
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI).
ONGLYZA™ US label update regarding use in renally impaired adults with type 2 diabetes
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has approved the inclusion of data from two clinical studies in an update to the ONGLYZA (saxagliptin) US Prescribing Information for adult type 2 diabetes patients.
Forest Laboratories to Acquire Clinical Data, Inc.
- Details
- Category: Financial
Forest Laboratories, Inc. (Forest) (NYSE: FRX) and Clinical Data, Inc. (Clinical Data) (NASDAQ: CLDA) have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics,
More Pharma News ...
- Novartis gains positive CHMP opinion for Rasilamlo(TM)
- Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right
- Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year
- Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement
- Lilly Marks Major Milestone for Mirror Portfolio
- First African country introduces GSK's pneumococcal vaccine
- New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin